FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwide

U.S. FDA — FDA today announced the Global Reliance Disclosure Program (GRDP), a landmark initiative that will fundamentally transform how the FDA's regulatory drug and biologic approval decisions are leveraged by health authorities around the world.

Read the original at U.S. FDA ↗

Auto-published by the finit.news Events monitor from U.S. FDA; summarized by AI and may contain errors — verify against the primary source. November 17, 2026.

By